Table of Contents

1 Study Coverage

• 1.1 Retinitis Pigmentosa Treatment Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Retinitis Pigmentosa Treatment Market Size Growth Rate by Product
  • 1.4.2 BNP-RP
  • 1.4.3 Cenegermin
  • 1.4.4 CPK-850
  • 1.4.5 Cutamesine
  • 1.4.6 FAB-111
  • 1.4.7 Others
• 1.5 Market by End User
  • 1.5.1 Global Retinitis Pigmentosa Treatment Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Homecare
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Retinitis Pigmentosa Treatment Market Size
  • 2.1.1 Global Retinitis Pigmentosa Treatment Revenue 2014-2025
  • 2.1.2 Global Retinitis Pigmentosa Treatment Sales 2014-2025
• 2.2 Retinitis Pigmentosa Treatment Growth Rate by Regions
  • 2.2.1 Global Retinitis Pigmentosa Treatment Sales by Regions
  • 2.2.2 Global Retinitis Pigmentosa Treatment Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Retinitis Pigmentosa Treatment Sales by Manufacturers
  • 3.1.1 Retinitis Pigmentosa Treatment Sales by Manufacturers
  • 3.1.2 Retinitis Pigmentosa Treatment Sales Market Share by Manufacturers
  • 3.1.3 Global Retinitis Pigmentosa Treatment Market Concentration Ratio (CR5 and HHI)
• 3.2 Retinitis Pigmentosa Treatment Revenue by Manufacturers
  • 3.2.1 Retinitis Pigmentosa Treatment Revenue by Manufacturers (2014-2019)
  • 3.2.2 Retinitis Pigmentosa Treatment Revenue Share by Manufacturers (2014-2019)
• 3.3 Retinitis Pigmentosa Treatment Price by Manufacturers
• 3.4 Retinitis Pigmentosa Treatment Manufacturing Base Distribution, Product Types
  • 3.4.1 Retinitis Pigmentosa Treatment Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Retinitis Pigmentosa Treatment Product Type
  • 3.4.3 Date of International Manufacturers Enter into Retinitis Pigmentosa Treatment Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Retinitis Pigmentosa Treatment Sales by Product
• 4.2 Global Retinitis Pigmentosa Treatment Revenue by Product
• 4.3 Retinitis Pigmentosa Treatment Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Retinitis Pigmentosa Treatment Breakdown Data by End User

6 North America

• 6.1 North America Retinitis Pigmentosa Treatment by Countries
  • 6.1.1 North America Retinitis Pigmentosa Treatment Sales by Countries
  • 6.1.2 North America Retinitis Pigmentosa Treatment Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Retinitis Pigmentosa Treatment by Product
• 6.3 North America Retinitis Pigmentosa Treatment by End User

7 Europe

• 7.1 Europe Retinitis Pigmentosa Treatment by Countries
  • 7.1.1 Europe Retinitis Pigmentosa Treatment Sales by Countries
  • 7.1.2 Europe Retinitis Pigmentosa Treatment Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Retinitis Pigmentosa Treatment by Product
• 7.3 Europe Retinitis Pigmentosa Treatment by End User

8 Asia Pacific

• 8.1 Asia Pacific Retinitis Pigmentosa Treatment by Countries
  • 8.1.1 Asia Pacific Retinitis Pigmentosa Treatment Sales by Countries
  • 8.1.2 Asia Pacific Retinitis Pigmentosa Treatment Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Retinitis Pigmentosa Treatment by Product
• 8.3 Asia Pacific Retinitis Pigmentosa Treatment by End User

9 Central & South America

• 9.1 Central & South America Retinitis Pigmentosa Treatment by Countries
  • 9.1.1 Central & South America Retinitis Pigmentosa Treatment Sales by Countries
  • 9.1.2 Central & South America Retinitis Pigmentosa Treatment Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Retinitis Pigmentosa Treatment by Product
• 9.3 Central & South America Retinitis Pigmentosa Treatment by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Retinitis Pigmentosa Treatment by Countries
  • 10.1.1 Middle East and Africa Retinitis Pigmentosa Treatment Sales by Countries
  • 10.1.2 Middle East and Africa Retinitis Pigmentosa Treatment Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Retinitis Pigmentosa Treatment by Product
• 10.3 Middle East and Africa Retinitis Pigmentosa Treatment by End User

11 Company Profiles

• 11.1 Astellas Pharma Inc.
  • 11.1.1 Astellas Pharma Inc. Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Astellas Pharma Inc. Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Astellas Pharma Inc. Retinitis Pigmentosa Treatment Products Offered
  • 11.1.5 Astellas Pharma Inc. Recent Development
• 11.2 Caladrius Biosciences, Inc.
  • 11.2.1 Caladrius Biosciences, Inc. Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Caladrius Biosciences, Inc. Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Caladrius Biosciences, Inc. Retinitis Pigmentosa Treatment Products Offered
  • 11.2.5 Caladrius Biosciences, Inc. Recent Development
• 11.3 Dompe Farmaceutici S.p.A.
  • 11.3.1 Dompe Farmaceutici S.p.A. Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Dompe Farmaceutici S.p.A. Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Dompe Farmaceutici S.p.A. Retinitis Pigmentosa Treatment Products Offered
  • 11.3.5 Dompe Farmaceutici S.p.A. Recent Development
• 11.4 Genable Technologies Limited
  • 11.4.1 Genable Technologies Limited Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Genable Technologies Limited Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Genable Technologies Limited Retinitis Pigmentosa Treatment Products Offered
  • 11.4.5 Genable Technologies Limited Recent Development
• 11.5 Genethon
  • 11.5.1 Genethon Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Genethon Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Genethon Retinitis Pigmentosa Treatment Products Offered
  • 11.5.5 Genethon Recent Development
• 11.6 GenSight Biologics S.A.
  • 11.6.1 GenSight Biologics S.A. Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 GenSight Biologics S.A. Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 GenSight Biologics S.A. Retinitis Pigmentosa Treatment Products Offered
  • 11.6.5 GenSight Biologics S.A. Recent Development
• 11.7 Grupo Ferrer Internacional, S.A.
  • 11.7.1 Grupo Ferrer Internacional, S.A. Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Grupo Ferrer Internacional, S.A. Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Grupo Ferrer Internacional, S.A. Retinitis Pigmentosa Treatment Products Offered
  • 11.7.5 Grupo Ferrer Internacional, S.A. Recent Development
• 11.8 ID Pharma Co., Ltd.
  • 11.8.1 ID Pharma Co., Ltd. Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 ID Pharma Co., Ltd. Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 ID Pharma Co., Ltd. Retinitis Pigmentosa Treatment Products Offered
  • 11.8.5 ID Pharma Co., Ltd. Recent Development
• 11.9 InFlectis BioScience
  • 11.9.1 InFlectis BioScience Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 InFlectis BioScience Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 InFlectis BioScience Retinitis Pigmentosa Treatment Products Offered
  • 11.9.5 InFlectis BioScience Recent Development
• 11.10 International Stem Cell Corporation
  • 11.10.1 International Stem Cell Corporation Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 International Stem Cell Corporation Retinitis Pigmentosa Treatment Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 International Stem Cell Corporation Retinitis Pigmentosa Treatment Products Offered
  • 11.10.5 International Stem Cell Corporation Recent Development
• 11.11 Ionis Pharmaceuticals, Inc.
• 11.12 M's Science Corporation
• 11.13 Mimetogen Pharmaceuticals Inc.
• 11.14 Nanovector s.r.l.
• 11.15 Orphagen Pharmaceuticals, Inc.

12 Future Forecast

• 12.1 Retinitis Pigmentosa Treatment Market Forecast by Regions
  • 12.1.1 Global Retinitis Pigmentosa Treatment Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Retinitis Pigmentosa Treatment Revenue Forecast by Regions 2019-2025
• 12.2 Retinitis Pigmentosa Treatment Market Forecast by Product
  • 12.2.1 Global Retinitis Pigmentosa Treatment Sales Forecast by Product 2019-2025
  • 12.2.2 Global Retinitis Pigmentosa Treatment Revenue Forecast by Product 2019-2025
• 12.3 Retinitis Pigmentosa Treatment Market Forecast by End User
• 12.4 North America Retinitis Pigmentosa Treatment Forecast
• 12.5 Europe Retinitis Pigmentosa Treatment Forecast
• 12.6 Asia Pacific Retinitis Pigmentosa Treatment Forecast
• 12.7 Central & South America Retinitis Pigmentosa Treatment Forecast
• 12.8 Middle East and Africa Retinitis Pigmentosa Treatment Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Retinitis Pigmentosa Treatment Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Retinitis Pigmentosa Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Retinitis Pigmentosa Treatment market based on company, product type, end user and key regions.

This report studies the global market size of Retinitis Pigmentosa Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Retinitis Pigmentosa Treatment in these regions.
This research report categorizes the global Retinitis Pigmentosa Treatment market by top players/brands, region, type and end user. This report also studies the global Retinitis Pigmentosa Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Astellas Pharma Inc.
Caladrius Biosciences, Inc.
Dompe Farmaceutici S.p.A.
Genable Technologies Limited
Genethon
GenSight Biologics S.A.
Grupo Ferrer Internacional, S.A.
ID Pharma Co., Ltd.
InFlectis BioScience
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
M's Science Corporation
Mimetogen Pharmaceuticals Inc.
Nanovector s.r.l.
Orphagen Pharmaceuticals, Inc.

Market size by Product
BNP-RP
Cenegermin
CPK-850
Cutamesine
FAB-111
Others
Market size by End User
Hospital
Clinic
Homecare

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Retinitis Pigmentosa Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Retinitis Pigmentosa Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Retinitis Pigmentosa Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Retinitis Pigmentosa Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Retinitis Pigmentosa Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Retinitis Pigmentosa Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.